Cardiovascular risk reduction with liraglutide: An exploratory mediation analysis of the leader trial

MLA

Linder, M., et al. Cardiovascular Risk Reduction with Liraglutide: An Exploratory Mediation Analysis of the Leader Trial. Jan. 2020. EBSCOhost, https://doi.org/10.17615/1rnr-dq63.

APA

Linder, M., Pocock, S., Zinman, B., Nissen, S. E., Nauck, M. A., Mann, J. F. E., Pratley, R. E., Fries, T. M., Buse, J. B., Ørsted, D. D., Poulter, N. R., & Bain, S. C. (2020). Cardiovascular risk reduction with liraglutide: An exploratory mediation analysis of the leader trial. https://doi.org/10.17615/1rnr-dq63

Chicago

Linder, M., S. Pocock, B. Zinman, S.E. Nissen, M.A. Nauck, J.F.E. Mann, R.E. Pratley, et al. 2020. “Cardiovascular Risk Reduction with Liraglutide: An Exploratory Mediation Analysis of the Leader Trial,” January. doi:10.17615/1rnr-dq63.